Medical Weight Loss with Ongoing Clinical Support
Achieve sustainable results with a medical plan
designed to transform your long-term health.
GPhC Registered
Pharmacy: 1088488
UK Clinician-Led Care
Expert support
Fast Delivery
Within 48 hours
100% Discreet
Plain packaging
Clinically-proven medication
Breakthrough solutions for sustainable weight results
Most effective dual action GLP-1
Mounjaro®
Mounjaro (Tirzepatide) patients lost up to 25% body weight after 72 weeks*- Helps manage appetite, reduce food noise and support metabolism
- Once-weekly injection
Approved to cut heart disease risk
Wegovy®
- Wegovy patients lost up to 15% body weight after 68 weeks*
- Contains semaglutide to help you feel fuller and manage cravings
- Weekly injection
How it works
Three simple steps to start treatment
Online Consultation
Complete a 2-minute health questionnaire. It's fast, confidential, and 100% secure.
Clinical Review
Our UK clinicians review your submission and review this within 24–48 hours.
Discreet Delivery
Your medication is shipped in plain packaging to your door. No branding, total privacy.
Why Addressing Your Weight Can
Transform Your Life
Carrying excess weight isn't a personal failing—it's a complex chronic condition influenced by genetics, metabolism, and environment. Research shows that even modest weight loss can deliver profound improvements in overall health and reduce the risk of serious conditions.
Proven Cardiovascular Improvement
Reduction in major cardiovascular events including heart attacks and strokes in patients with existing cardiovascular disease and obesity.
Reducing Risk of Type-2 Diabetes
Progression from prediabetes to type 2 diabetes reduced by over 13× compared to placebo groups.
Reducing Cancer Risk
Significant reductions in endometrial and ovarian cancer risk observed in clinical studies.
Reduction in Joint Pain
Lower knee joint pressure leads to improvements in pain, mobility and physical function.
Real results
Rated Excellent on Trustpilot
“I've changed my whole wardrobe! I can now shop at so many more shops that I couldn’t before.”
Sarah, UK
“I now can keep up better with my grandchildren. My weight isn't holding me back anymore.”
David, UK
“The price is much better than other sites I've used, and the service is just as professional.”
Eloise, UK
Safe, sustainable weight
management led by experts
Clinically-proven medication
Breakthrough solutions for sustainable weight loss results
Medical Oversight
Led by qualified UK prescribers & clinicians specialised in weight management.
Safety First
Rigorous screening & ongoing monitoring. We prioritise your health above all else. Your data is encrypted, secure, and entirely confidential.
Unbeatable Clinical Support
Beyond the provision of medication, we offer exceptional clinical support, which is easy to access via your dashboard.
Clinically Proven Results
GLP-1 medications deliver significantly greater weight loss compared to diet and exercise alone
Up to 25% Weight Loss*
Alongside a healthy diet and exercise.
Life Changing Results
Reduces food noise and cravings.
Treatments Start from —
One-off or optional subscription. No lock-in contract.
Full medical
history review
Risk assessment
& safety check
Discussion of
your treatment
Ongoing reviews
at every order
*Mounjaro (Tirzepatide) patients lost up to 25% body weight after 72 weeks
GLP-1 Weight Loss Treatment
Transparent pricing for your weight loss journey
Our clinicians will determine the optimal dose for you—whether you're starting treatment or switching from another provider. This decision is based on your medical history, current
health status, and treatment goals.
The comprehensive breakdown below shows all available doses for complete transparency. Your clinician's decision is final and made in your best medical interest.
Wegovy
Semaglutide · Weekly Injection
Starting from
— /mo
0.25mgStarting dose
Initial dose for tolerance assessment
—
per month
0.5mgEarly titration
Early titration phase
—
per month
1.0mgProgressive increase
Progressive dose increase
—
per month
1.7mgHigher dose
Higher therapeutic dose
—
per month
2.4mgMaximum dose
Full licensed dose—common maintenance for many patients
—
per month
Mounjaro
Tirzepatide · Weekly Injection
Starting from
— /mo
2.5mgStarting dose
Starting dose to assess tolerance and side effects
—
per month
5.0mgPopular choice
Where most patients notice significant appetite reduction
—
per month
7.5mgMid-range
Mid-range therapeutic dose
—
per month
10mgSweet spot
Optimal balance between further weight loss and cost
—
per month
12.5mgHigher dose
Higher therapeutic dose for continued progress
—
per month
15mgMaximum dose
Full licensed dose for maximum therapeutic effect
—
per month
Clinical Note:
Wegovy and Mounjaro do not have direct bioequivalence. If you're switching from one medication to another, our clinicians will work with you to determine the most appropriate dose based on your previous response and current treatment goals.
Important Information
• We do not guarantee specific weight loss results; individual bodies respond differently.
• Treatment is NOT guaranteed; it is subject to strict medical assessment during consultation.
• Medicines are determined case-by-case by qualified clinicians based on your safety profile.
Clinical expertise you can trust
"Our service is dedicated to evidence-based care and patient safety. Every treatment decision is made with your health as the priority."
Suhail Khan
Clinical Director | GPhC: 2082431
Latest from our Knowledge Hub
Evidence-based insights on weight management from our clinical team.
Frequently Asked Questions
Generally, you're eligible if you have a BMI of 30+ (or 27+ with weight-related health conditions). During your consultation, our clinicians assess your medical history and medications. We cannot prescribe if you're pregnant, breastfeeding, have certain thyroid cancers, or a history of pancreatitis.
Contact us with any more questions via contact us page
References
*Based on a 72-week study of adults with obesity using
Mounjaro (tirzepatide 15mg)
Reference: Jastreboff et al. SURMOUNT-1 Investigators (2022) Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine.
*Based on a 68-week study of adults with obesity using
Wegovy (semaglutide 2.4mg)
Wilding et al. and STEP 1 Study Group (2021) Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), pp.989–1002.